Novo Nordisk
$72.659876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$72.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.67 (+0.93%) As of 3:59 PM UTC today
Why Robinhood?
You can buy or sell Novo Nordisk and other stocks, options, and ETFs commission-free!
About NVO
Novo-Nordisk A/S, also called Novo Nordisk, is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark. The listed name for NVO is Novo-Nordisk A/S.
CEO
Lars Fruergaard Jørgensen
Employees
43,258
Headquarters
Bagsværd, Capital Region
Founded
1925
Market Cap
167.84B
Price-Earnings Ratio
27.45
Dividend Yield
1.27
Average Volume
1.05M
High Today
$72.73
Low Today
$72.42
Open Price
$72.69
Volume
312.34K
52 Week High
$73.92
52 Week Low
$49.24
Collections
Analyst Ratings
52%
of 27 ratings
Buy
52%
Hold
33%
Sell
15%
NVO Earnings
$0.00
$0.25
$0.51
$0.76
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 3, Pre-Market